NASDAQ$INKT
Mink Therapeutics Inc · Q4 2023 earnings
Q4 2023 earnings · · Investor relations
Briefing
Reported fourth quarter and full-year 2023 results.
MiNK Therapeutics reported its Q4 and full-year 2023 financial results, highlighting the progression of its lead program, agenT-797, into a Phase 2 study in gastroesophageal cancers. The company ended the year with a cash balance of $3.4 million and reported a net loss for the year of $22.5 million, or $0.65 per share.
- Advanced allogeneic iNKT cell programs, contributing to clinical data.
- Expanded pipeline and solidified partnerships, including a research agreement with ImmunoScape.
- Progressed agenT-797 into a Phase 2 study in gastroesophageal cancers.
- Anticipate sharing initial trial data later this year.
Headline financials
Revenue & EPS history
Mink Therapeutics · Revenue · Quarterly
-$11.7B
Forward guidance
MiNK Therapeutics is focused on advancing its lead program, agenT-797, particularly in indications with promising proof-of-concept data and anticipates sharing initial trial data later this year.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 18 quarterly earnings reports · overlaid with Q4 2023
-3.6%
Avg return
Earnings day
-4.9%
Avg return
5 days after
-1.7%
Avg return
30 days after
42%
8 / 19 earnings
Positive
+14.6%
Q3 2022
Best reaction
-42.0%
Q2 2021
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2026 | +3.9% | +2.2% | +13.3% | |
| Q3 2025 | -1.9% | -16.6% | -6.1% | |
| Q2 2025 | -13.6% | -16.0% | -17.7% | |
| Q1 2025 | -3.3% | -3.8% | -3.3% | |
| Q4 2024 | -3.3% | +6.8% | -14.9% | |
| Q3 2024 | -5.0% | -13.5% | -22.4% | |
| Q2 2024 | +0.6% | -3.0% | -8.5% | |
| Q1 2024 | +6.1% | +3.1% | -1.4% | |
| Q4 2023 | -2.9% | +4.7% | -2.2% | |
| Q3 2023 | -11.8% | -20.2% | -14.3% | |
| Q2 2023 | +1.7% | -5.0% | -26.1% | |
| Q1 2023 | +13.9% | +11.3% | +44.4% | |
| Q4 2022 | +0.5% | -3.4% | -3.4% | |
| Q3 2022 | +14.6% | +17.8% | +18.3% | |
| Q2 2022 | +13.2% | +25.7% | +114.7% | |
| Q1 2022 | -26.7% | -26.7% | -13.1% | |
| Q4 2021 | -6.1% | -4.2% | -5.5% | |
| Q3 2021 | -6.1% | -4.2% | -5.5% | |
| Q2 2021 | -42.0% | -47.6% | -78.6% | |
| Q1 2021 | — | — | — | |
| Q4 2020 | — | — | — | |
| Q3 2020 | — | — | — | |
| Q2 2020 | — | — | — | |
| Q1 2020 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro